Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14098038 | 1.00 | REN (0.81) | REN | |
| SCHEMBL1596612 | 1.00 | REN (0.81) | REN | |
| SCHEMBL4640194 | 0.93 | REN (0.77) | REN | |
| SCHEMBL430240 | 0.93 | REN (0.77) | REN | |
| SCHEMBL14098041 | 0.93 | REN (0.77) | REN | |
| SCHEMBL4641129 | 0.93 | REN (0.77) | REN | |
| SCHEMBL4474654 | 0.93 | REN (0.77) | REN | |
| SCHEMBL8238828 | 0.91 | REN (0.85) | REN | |
| SCHEMBL14098298 | 0.91 | REN (0.85) | REN | |
| SCHEMBL8260192 | 0.91 | REN (0.85) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408427-A1 | GALENICAL FORMULATIONS OF A FIXED DOSE COMBINATION OF VALSARTAN AND ALISKIREN | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408433-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ALISKIREN | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107971-A1 | GALENICAL FORMULATIONS OF A FIXED DOSE COMBINATION OF VALSARTAN AND ALISKIREN | NOVARTIS AG (CH) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107966-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ALISKIREN | NOVARTIS AG (CH) | 2010-09-23 | — | — | WO | disclosed |
| US-20080167381-A1 | 5-Amino-4-Hydroxy-2-Isopropyl-7-[4-Methoxy-3-(3-Methoxypropoxy)Benzyl]-8-Methylnonamides | SPEEDEL EXPERIMENTA AG (CH) | 2008-07-10 | — | — | US | disclosed |
| EP-1867329-A3 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1867329-A2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867329-A2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| CN-101076518-A | 5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropxy)benzyl]-8-methylnonanamides | SPEEDEL EXPERIMENTA AG (CH) | 2007-11-21 | — | — | CN | disclosed |
| EP-1819675-A1 | 5-AMINO-4-HYDROXY-2-ISOPROPYL-7-Ý4-METHOXY-3-(3-METHOXYPROPXY)BENZYL¨-8-METHYLNONANAMIDES | Speedel Experimenta AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006061427-A1 | 5-AMINO-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPXY)BENZYL]-8-METHYLNONANAMIDES | SPEEDEL EXPERIMENTA AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167381-A1 | 5-Amino-4-Hydroxy-2-Isopropyl-7-[4-Methoxy-3-(3-Methoxypropoxy)Benzyl]-8-Methylnonamides | REN, AGTR1, AGTR2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.